IL1B and plasma cell myeloma: There is contrary evidence from a limited number of studies that IL-1β can have tumor-inhibiting effects, specifically by inducing both T helper cell 1 (Th1) and Th17 anti-tumorigenic effects in myeloma and lymphoma (88).